Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance

Published: Wednesday, October 23, 2013
Last Updated: Wednesday, October 23, 2013
Bookmark and Share
Under the terms of the agreement, Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects.

This new alliance adds an integral component to Sygnature’s ‘federated’ CRO Model, which provides fully-integrated drug discovery services to the pharmaceutical industry.

Dr Torsten Neuefeind, CEO, Co-founder at Proteros said, "Sygnature has a growing reputation as a provider of premium integrated drug discovery services.  Proteros has worked with Sygnature on a number of drug discovery projects, so we already have an established working relationship.  This strategic alliance combines the complementary skills of Proteros and Sygnature Discovery.  Proteros will continue to provide X-ray protein structure analysis independently, but will also be able to contribute to fully-integrated drug discovery programmes via Sygnature’s ‘federated’ CRO model.  Working closely together on drug discovery projects, we are confident that Proteros and Sygnature can advance clients’ programmes more efficiently and effectively.”

Commenting on the strategic alliance, Dr Simon Hirst, Sygnature’s CEO said, “Proteros has specialist skills in early stage drug discovery that are highly-complementary to our own.  Proteros has an outstanding reputation for providing unique and best-in-class technologies for X-ray protein crystallography, kinetic and thermodynamic profiling and tailor-made protein production.  Sygnature and Proteros have already collaborated on a number of challenging client projects.  The close working relationship that we have established will be cemented through this strategic alliance.  With the addition of Proteros to the ‘federated’ CRO Model, it enables Sygnature to offer its customers a world class, fully-integrated drug discovery service where novel compounds can be designed, synthesised and screened in vitro at Sygnature, X-ray protein structure analysis undertaken at Proteros, metabolic liability and toxicity assessed at Cyprotex and then tested at Saretius and Pneumolabs in pharmocodynamic and disease-relevant models.  This powerful federation of alliance partners will help accelerate our clients’ drug discovery programmes towards development.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sygnature Discovery Strengthens Team with Three Key Appointments
Company appoints Dr Tim Schulz-Utermoehl, Dr Martin Quibell and Dr Scott Pollack.
Saturday, January 31, 2015
Controlling Gas Liquid Chemistries
Sygnature Discovery has reported results demonstrating how the Uniqsis FlowSyn™ flow reactor system allows them to perform traditionally hazardous chemistries in a controlled manner.
Monday, January 21, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Rice Disease-Resistance Discovery Closes the Loop for Scientific Integrity
Researchers reveal how disease resistant rice detects and responds to bacterial infections.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!